Isradipine does not slow clinical progression of Parkinson's disease
In epidemiologic studies, dihydropyridine calcium-channel blockers have been associated with reduced risk for Parkinson's disease (PD).
The researchers conducted a phase III, multicenter, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate isradipine, one such calcium-channel blocker, as a treatment to slow PD progression.
They found that long-term treatment with immediate-release isradipine does not seem to slow the clinical progression of early-stage Parkinson's disease.
The findings of the trial have been published in Annals of Internal Medicine.
Despite multiple prior studies, there are no proven strategies for slowing the progression of Parkinson's disease. Isradipine, a dihydropyridine calcium-channel blocker approved for the treatment of hypertension, has been shown to be neuroprotective in animal models Parkinson's disease. Several epidemiologic studies have demonstrated a reduced risk for Parkinson's disease in persons receiving dihydropyridines compared with other antihypertensive agents, leading researchers to hypothesize that isradipine may have the potential to slow the progression of the disease when used in its early stages.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.